KDM5A and acute myeloid leukemia: Ex vivo drug sensitivity assays have also been performed using retroviral transduction models, identifying BRD2/4 inhibitors, topoisomerase II inhibitors, and gemcitabine as effective in NUP98-KDM5A AML (76).